Hidden Clicker Hidden Clicker
首頁 > 館藏查詢 > 書目資料
後分類 X

目前查詢

歷史查詢

Pediatric cancer therapeutics development /
切換:
  • 簡略
  • 詳細(MARC)
  • ISBD
  • 分享

Pediatric cancer therapeutics development /

紀錄類型 : 書目-語言資料,印刷品: 單行本

其他作者 : DiMartino, Jorge,

出版者 : Cham, Switzerland :Springer,2022.

面頁冊數 : 1 online resource.

內容註 : Intro -- Contents -- 1: History of Drug Development for Children with Cancer -- 1.1 Introduction -- 1.2 Initial Progress -- 1.3 Rise of the Cancer Cooperative Groups -- 1.4 Impact of Regulation to Improve Safety and Efficacy Federal Laws Providing a Regulatory Framework for Drug Development in Children -- 1.5 Indications -- 1.6 Summary -- References -- 2: Targeted Small Molecule Drug Discovery -- 2.1 Introduction -- 2.2 Stage Gating -- 2.3 Phenotypic Drug Discovery -- 2.4 Target-Based Drug Discovery: Considerations for Target Selection/Identification

內容註 : 2.5 Target-Based Drug Discovery: Identifying Chemical Starting Points -- 2.6 Hit-to-Lead -- 2.7 Lead Optimization -- 2.8 Candidate Nomination -- References -- 3: An FDA Oncology Perspective of Juvenile Toxicity Studies to Support Pediatric Drug Development -- 3.1 Introduction -- 3.2 Should a JAS Be Considered? -- 3.2.1 ICH S11: Nonclinical Safety Testing in Support of Development of Pediatric Medicines -- 3.2.2 ICH S9: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers -- 3.3 Dinutuximab and Naxitamab -- 3.4 TRK Inhibitors -- 3.5 Conclusion -- References

內容註 : 4: Design and Statistical Considerations for Early Phase Clinical Trials in Pediatric Oncology -- 4.1 Introduction -- 4.2 Rule-Based Designs -- 4.2.1 Traditional 3 + 3 Design -- 4.2.2 Accelerated Titration Design -- 4.2.3 Rolling Six Design -- 4.3 Model-Based Designs -- 4.3.1 Continual Reassessment Method (CRM) -- 4.3.2 EWOC and BLRM -- 4.3.3 TITE-CRM and TITE-EWOC -- 4.4 Model-Assisted Designs -- 4.4.1 Modified Toxicity Probability Interval (mTPI) Design -- 4.4.2 Keyboard Design -- 4.4.3 Bayesian Optimal Interval (BOIN) Design -- 4.5 New Designs -- 4.5.1 Modified 4 + 4 Design

內容註 : 4.6 Conclusions -- References -- 5: Exploratory Clinical Development: From First in Humans to Phase 3 Ready -- 5.1 Introduction -- 5.2 The Therapeutic Hypothesis -- 5.3 Dose and Schedule Determination -- 5.4 Clinical Proof of Concept (PoC) -- 5.5 Putting It All Together: Combined Phase 1-2 Studies -- 5.6 A Role for Pediatric Cancer in Exploratory Drug Development -- References -- 6: Gene and Cell Therapy: How to Build a BioDrug -- 6.1 Introduction -- 6.2 BioDrug ToolKit: Cells -- 6.2.1 Hematopoietic Stem Cells (HSCs) -- 6.2.2 T Lymphocytes -- 6.2.3 Natural Killer (NK) Cells

標題 : Cancer in children - Treatment. -

標題 : Cancer - Chemotherapy. -

標題 : Drug development. -

標題 : Children. -

標題 : Human beings. -

標題 : Pediatrics. -

標題 : Therapeutics. -

標題 : Neoplasms - therapy -

標題 : Child -

標題 : Humans -

標題 : Pediatrics -

標題 : Therapeutics -

ISBN : 9783031063572

ISBN : 3031063570

LEADER 03624nam 2200385 a 4500

001 49819

003 NhCcYBP

005 20240428142059.5

006 m o d

007 cr |n|||||||||

008 221122s2022 sz o 000 0 eng d

020 $a9783031063572$q(electronic bk.)

020 $a3031063570$q(electronic bk.)

020 $z3031063562

020 $z9783031063565

024 7 $a10.1007/978-3-031-06357-2$2doi

035 $aebs3460618

040 $aNhCcYBP$cNhCcYBP

041 $aeng

050 4$aRC281.C4$bP43 2022

072 7$aMJCL$2bicssc

072 7$aMED062000$2bisacsh

072 7$aMJCL$2thema

082 04$a618.9299406$223/eng/20221202

245 00$aPediatric cancer therapeutics development /$cJorge DiMartino, Gregory H. Reaman, Franklin O. Smith, editors.

260 $aCham, Switzerland :$bSpringer,$c2022.

300 $a1 online resource.

490 1 $aPediatric Oncology

505 0 $aIntro -- Contents -- 1: History of Drug Development for Children with Cancer -- 1.1 Introduction -- 1.2 Initial Progress -- 1.3 Rise of the Cancer Cooperative Groups -- 1.4 Impact of Regulation to Improve Safety and Efficacy Federal Laws Providing a Regulatory Framework for Drug Development in Children -- 1.5 Indications -- 1.6 Summary -- References -- 2: Targeted Small Molecule Drug Discovery -- 2.1 Introduction -- 2.2 Stage Gating -- 2.3 Phenotypic Drug Discovery -- 2.4 Target-Based Drug Discovery: Considerations for Target Selection/Identification

505 8 $a2.5 Target-Based Drug Discovery: Identifying Chemical Starting Points -- 2.6 Hit-to-Lead -- 2.7 Lead Optimization -- 2.8 Candidate Nomination -- References -- 3: An FDA Oncology Perspective of Juvenile Toxicity Studies to Support Pediatric Drug Development -- 3.1 Introduction -- 3.2 Should a JAS Be Considered? -- 3.2.1 ICH S11: Nonclinical Safety Testing in Support of Development of Pediatric Medicines -- 3.2.2 ICH S9: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers -- 3.3 Dinutuximab and Naxitamab -- 3.4 TRK Inhibitors -- 3.5 Conclusion -- References

505 8 $a4: Design and Statistical Considerations for Early Phase Clinical Trials in Pediatric Oncology -- 4.1 Introduction -- 4.2 Rule-Based Designs -- 4.2.1 Traditional 3 + 3 Design -- 4.2.2 Accelerated Titration Design -- 4.2.3 Rolling Six Design -- 4.3 Model-Based Designs -- 4.3.1 Continual Reassessment Method (CRM) -- 4.3.2 EWOC and BLRM -- 4.3.3 TITE-CRM and TITE-EWOC -- 4.4 Model-Assisted Designs -- 4.4.1 Modified Toxicity Probability Interval (mTPI) Design -- 4.4.2 Keyboard Design -- 4.4.3 Bayesian Optimal Interval (BOIN) Design -- 4.5 New Designs -- 4.5.1 Modified 4 + 4 Design

505 8 $a4.6 Conclusions -- References -- 5: Exploratory Clinical Development: From First in Humans to Phase 3 Ready -- 5.1 Introduction -- 5.2 The Therapeutic Hypothesis -- 5.3 Dose and Schedule Determination -- 5.4 Clinical Proof of Concept (PoC) -- 5.5 Putting It All Together: Combined Phase 1-2 Studies -- 5.6 A Role for Pediatric Cancer in Exploratory Drug Development -- References -- 6: Gene and Cell Therapy: How to Build a BioDrug -- 6.1 Introduction -- 6.2 BioDrug ToolKit: Cells -- 6.2.1 Hematopoietic Stem Cells (HSCs) -- 6.2.2 T Lymphocytes -- 6.2.3 Natural Killer (NK) Cells

533 $aElectronic reproduction.$bIpswich, MA$nAvailable via World Wide Web.

588 0 $aOnline resource; title from PDF title page (SpringerLink, viewed December 2, 2022).

650 0$aCancer in children$xTreatment.$393371

650 0$aCancer$xChemotherapy.$2fast$369344

650 0$aDrug development.$380152

650 0$aChildren.$377021

650 0$aHuman beings.$390519

650 0$aPediatrics.$323810

650 0$aTherapeutics.$331633

650 12$aNeoplasms$xtherapy$311809

650 22$aChild$320

650 22$aHumans$329864

650 22$aPediatrics$311876

650 22$aTherapeutics$313298

700 1 $aDiMartino, Jorge,$eeditor.$393372

700 1 $aReaman, Gregory H.$eeditor.$393373

700 1 $aSmith, Franklin O.$eeditor.$393374

710 2 $aEBSCOhost$387894

776 08$cOriginal$z3031063562$z9783031063565

830 0$aPediatric oncology (Series)$393370

856 40$uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3460618$zClick to View (限總院院內)

Pediatric cancer therapeutics development /Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith, editors. - Cham, Switzerland :Springer,2022. - 1 online resource. - Pediatric Oncology. - Pediatric oncology (Series).

Intro -- Contents -- 1: History of Drug Development for Children with Cancer -- 1.1 Introduction -- 1.2 Initial Progress -- 1.3 Rise of the Cancer Cooperative Groups -- 1.4 Impact of Regulation to Improve Safety and Efficacy Federal Laws Providing a Regulatory Framework for Drug Development in Children -- 1.5 Indications -- 1.6 Summary -- References -- 2: Targeted Small Molecule Drug Discovery -- 2.1 Introduction -- 2.2 Stage Gating -- 2.3 Phenotypic Drug Discovery -- 2.4 Target-Based Drug Discovery: Considerations for Target Selection/Identification


Electronic reproduction.
Ipswich, MA





Available via World Wide Web.

ISBN: 9783031063572

Standard No.: 10.1007/978-3-031-06357-2doiSubjects--Topical Terms:

93371
Cancer in children
--Treatment.

LC Class. No.: RC281.C4 / P43 2022

Dewey Class. No.: 618.9299406
  • 館藏(0)
  • 心得(0)
  • 標籤
  • 相同喜好的讀者(0)
  • 相關資料(0)

歡迎將此書加入書櫃

Hidden Clicker Hidden Clicker Hidden Clicker Hidden Clicker Hidden Clicker Hidden Clicker Hidden Clicker Hidden Clicker Hidden Clicker Hidden Clicker Hidden Clicker